Glow70
Why study several peptides together rather than one? Glow70 combines three peptides already documented separately, which raises a question of scientific reading in itself.
- Research Use Only
- Molecule under study
- Living document
View the corresponding reference in the shop
- Current research state
- An experimental complex combining three peptides individually studied in preclinical and cosmetic research.
- Current clinical phase
- No clinical trial dedicated to the combination — available data concern each peptide separately.
- Last update
- 21 July 2026 · Reference fact sheet v1.0
- Living document
- Updated regularly as research progresses.
What is Glow70?
Glow70 is not a single molecule but a research complex combining three distinct peptides in a single lyophilized vial.
Each peptide in Glow70 has its own scientific literature — the idea behind the combination is to bring together complementary mechanisms studied in tissue repair and skin quality.
The complex is presented for educational and reference purposes. No clinical trial has validated the combination as such in humans.
Names you may come across
This molecule may appear under several names in the scientific, clinical or technical literature. Here are the main designations you may come across.
Name of the PHL complex, total content 70 mg.
Technical description of the formulation.
Common community term for this type of combination.
Understanding it simply
Three simple reference points for understanding Glow70.
Three peptides, three areas
GHK-Cu is studied on the skin matrix, BPC-157 on repair; for TB-500, cell migration data come mainly from full-length thymosin β4.
A complex, not a medicine
Glow70 is a research vial. No human clinical trial has been conducted on this specific combination.
A total content, multiple peptides
The stated 70 mg represents the sum of the three peptides — each has its own individual content.
What research shows today
Science advances step by step. We clearly distinguish what is firmly established from what remains under study.
- GHK-Cu: extensively documented in vitro effects and topical cosmetic effects. — established
- BPC-157: numerous preclinical studies on tissue repair (rodents). — established
- TB-500 is a synthetic fragment of thymosin β4; most published preclinical studies concern full-length thymosin β4, not this fragment. — established
- Human clinical data for the fixed combination: absent. — ongoing
- Pharmacokinetics and interactions between the three peptides in vivo: to be clarified. — ongoing
Each component is individually documented; the fixed combination remains under study as a research protocol, without dedicated clinical trials of the complex.
What the research shows
- GHK-Cu: collagen and elastin synthesis, antioxidant effects, and well-tolerated topical cosmetic use.
- BPC-157: wound-healing effects documented in numerous preclinical models (tendon, muscle, gastrointestinal tract).
- Full-length thymosin β4: cell migration, angiogenesis and actin binding described preclinically; these results cannot be directly transposed to the TB-500 fragment.
What still remains to be studied
- Pharmacokinetic behavior of the mixture in humans — not characterized.
- Potential synergies or antagonisms between the three peptides — not studied clinically.
- Long-term tolerability of the fixed combination — unknown.
What we know today
Not all information carries the same weight of evidence. We therefore present it across three clearly distinct levels, from the most solid to the most indicative.
What scientific publications show
Scientific evidence- The scientific literature addresses each peptide separately; few publications examine their simultaneous combination in a single vial.
- Combinations of GHK-Cu and repair peptides are being explored in experimental dermatology research.
What some professionals report
Documented- Some cosmetic formulators use GHK-Cu in synergy with other topical peptides, with a favorable tolerability profile.
- There is no clinical consensus on the ideal proportions for this type of complex for systemic use.
What the community reports
Field observations- Community feedback mainly concerns experimental uses, without standardization or objective data.
- Individual observations do not replace clinical trials.
The level of evidence for the Glow70 complex is uneven: strong for each peptide individually, very limited for the combination.
How does Glow70 work?
Glow70 explores three distinct biological areas through its three components.
- Skin fibroblasts (GHK-Cu)
- Possible effects on the production of collagen, elastin and other tissue-supporting materials.
- Tissue repair pathways (BPC-157)
- Modulation of growth factors and wound healing studied in several preclinical models.
- Actin cytoskeleton (thymosin β4)
- Actin binding and the effect on cell migration are described for full-length thymosin β4; whether the TB-500 fragment retains them is poorly documented.
- Angiogenesis (thymosin β4 / BPC-157)
- Formation of new vessels described in several preclinical studies, contributing to tissue recovery.
These mechanisms are described for each peptide individually. Combining them in a single vial does not mean that additive effects have been demonstrated.
Clinical trials timeline
A molecule under study progresses step by step. Here, simply, is where the research currently stands.
- Research· 1970s-1980sCompleted
Isolation of GHK and characterization of its copper complex
The scientific foundations for the GHK-Cu component are established.
- Research· 1990s-2000sCompleted
Preclinical studies of BPC-157
Numerous published animal models of tissue repair.
- Research· 2000sCompleted
Characterization of thymosin β4
Preclinical studies on full-length thymosin β4 (cell migration, angiogenesis); the TB-500 fragment has been studied far less.
- Formulation· CurrentlyOngoing
Multi-peptide complexes in research
Emergence of fixed combinations to explore complementary mechanisms — not clinically validated.
Available analyses
Analytical documents provided by suppliers and published for Glow70, available in the Analysis Library. They document batch traceability and are not an independent analysis performed by PHL.
Open the analysis libraryFrequently asked questions
Is Glow70 a medicine?
No. It is a research complex (Research Use Only). No therapeutic use is suggested.
Why combine three peptides in a single vial?
To be studied: the aim is to explore complementary mechanisms (skin matrix, repair, cell migration). The clinical value of a fixed combination has not been demonstrated.
Do the GHK-Cu data apply to Glow70?
In part. They concern GHK-Cu alone — adding BPC-157 and TB-500 potentially changes the biological context.
Are there clinical trials on Glow70?
No. To our knowledge, there is no clinical trial dedicated to this specific combination in humans.
How does it differ from Klow80?
Klow80 adds the peptide KPV (10 mg) to the formulation, with a focus on research into inflammatory responses.
Scientific publications
Reference bibliography covering each peptide individually — no publication specifically addresses the Glow70 complex.
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P. et al. · Current Pharmaceutical Design · 2013
Thymosin β4: actin-sequestering protein moonlights to repair injured tissues
Goldstein A. L., Hannappel E., Kleinman H. K. · Trends in Molecular Medicine · 2005
Thymosin β4: structure, function, and biological properties supporting current and future clinical applications
Crockford D. et al. · Annals of the New York Academy of Sciences · 2010
Glossary
- Complex
- Combination of several molecules in a single formulation.
- Lyophilisation
- Freeze-drying under vacuum, which stabilizes peptides in powder form.
- Angiogenesis
- Formation of new blood vessels from existing vessels.
- Fibroblast
- A connective-tissue cell that makes collagen and other material supporting nearby cells.
- Extracellular matrix
- A network of proteins that supports cells within a tissue.
Continue your discovery
Read next
Sheets that are thematically close. These links serve reading and discovery — they suggest no combined use.
Reference fact sheet — version 1.0, updated on 21 July 2026. The full regulatory and scientific framework is gathered in the “Important information” box at the top of the fact sheet.
Explore the fundamentals related to this goal
This general content is independent of the molecule and is neither a use strategy nor a protocol.